{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:42:06Z","timestamp":1784410926406,"version":"3.55.0"},"reference-count":13,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background<\/jats:title>\n<jats:p>Switching of biologics in patients has become common in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study investigated the reasons for and effectiveness of switching biologic agents during the treatment of psoriasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively reviewed patients with psoriasis who were treated with biologics at Pusan National University Hospital and Chosun University Hospital from March 2012 to June 2020. We assessed their demographics and treatment characteristics (reasons for switching biologics and efficacy of the first- and second biologic agents).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 162 psoriatic patients treated with biologic agents for more than 52 weeks, 35 required a switch to another biologic agent. The reasons for switching biologic agents were inefficacy (<jats:italic>n<\/jats:italic> = 30), adverse events (<jats:italic>n<\/jats:italic> = 2) and others (<jats:italic>n<\/jats:italic> = 3). The mean psoriasis area and severity index (PASI) score was 12.1 at the start of the second biologic and 3.4 at 14\u201316 weeks later. Patients were more likely to switch to another biologic agent when they exhibited a high initial psoriasis area and severity index score and concomitant psoriatic arthritis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Limitations<\/jats:title>\n<jats:p>As a retrospective study, there were some limitations such as lack of a placebo control group and the time point of 14\u201316 weeks being somewhat early to judge the effect of the biologics.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st6\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The most common reason for switching biologic agents in Korea was treatment inefficacy, especially secondary failure. Despite the inefficacy of previous biologic agents, switching to a different agent may be an efficacious approach.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_308_2022","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T12:35:04Z","timestamp":1685363704000},"page":"928-928","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea"],"prefix":"10.25259","volume":"89","author":[{"given":"Jun-Oh","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Seok","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chosun University Hospital, Gwangju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Nam","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyuk","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Chang","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Bum","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pusan National University Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"10.25259\/IJDVL_308_2022\/ref-1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0190-9622(99)70112-x","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.11.001","article-title":"Psoriasis as a systemic disease","volume":"32","author":"Grozdev","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-4","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2133.2009.09030.x","article-title":"Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response","volume":"160","author":"Rakkhit","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_308_2022\/ref-7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1468-3083.2009.03093.x","article-title":"Etanercept in severe, recalcitrant psoriasis: Clinical response, safety profile and predictors of response based on a single institution\u2019s experience","volume":"23","author":"Antoniou","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_308_2022\/ref-8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1346-8138.14834","article-title":"Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry","volume":"46","author":"Bayaraa","year":"2019","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/1346-8138.13860","article-title":"Switching of biologics in psoriasis: Reasons and results","volume":"44","author":"Honda","year":"2017","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504839","article-title":"Switching biologics in the treatment of psoriasis: A multicenter experience","volume":"237","author":"\u00d6zkur","year":"2021","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_308_2022\/ref-11","first-page":"617","article-title":"Efficacy and safety of ustekinumab in the treatment of moderate to severe psoriasis in Korea","volume":"53","author":"Park","year":"2015","journal-title":"Korean J Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-12","first-page":"9","article-title":"Efficacy and safety of secukinumab for the treatment of moderate to severe psoriasis in Korea","volume":"57","author":"Ha","year":"2019","journal-title":"Korean J Dermatol"},{"key":"10.25259\/IJDVL_308_2022\/ref-13","first-page":"389","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate to severe psoriasis in Korea","volume":"58","author":"Won","year":"2020","journal-title":"Korean J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/review-of-the-reasons-for-and-effectiveness-of-switching-biologics-for-psoriasis-treatment-in-korea\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/review-of-the-reasons-for-and-effectiveness-of-switching-biologics-for-psoriasis-treatment-in-korea\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T05:48:29Z","timestamp":1698472109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/review-of-the-reasons-for-and-effectiveness-of-switching-biologics-for-psoriasis-treatment-in-korea\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":13,"alternative-id":["10.25259\/IJDVL_308_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_308_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,28]]},"article-number":"928"}}